Box Adrian, Alshalalfa Mohammed, Hegazy Samar A, Donnelly Bryan, Bismar Tarek A
Department of Pathology and Laboratory Medicine, University of Calgary and Calgary Laboratory Services, Calgary, Alberta, Canada.
The Prostate Cancer Center, Calgary, Alberta, Canada.
Tumour Biol. 2016 Sep;37(9):12287-12299. doi: 10.1007/s13277-016-5075-1. Epub 2016 Jun 7.
Alpha-methylacyl-CoA racemase (AMACR) is a well-characterized marker extensively utilized in prostate cancer (PCA) diagnosis. However, the prognostic value of AMACR expression and its relation to TMPRSS2-ERG gene rearrangement as one of the most common molecular alterations in PCA is not fully explored. AMACR expression was investigated in a cohort of 218 men with localized PCA treated by radical prostatectomy and correlated with ERG and various clinical and pathological parameters. In vitro studies assessed AMACR changes to ERG knockdown and other related genes. In addition, bioinformatics validated the significance of AMACR/ERG expression and assessed relevant genetic signatures in relation to AMACR/ERG expression. AMACR expression was significantly associated with disease progression and with ERG (p ∼0). Seventeen percent of cancer foci showed negative/weak AMACR expression while being ERG positive. High AMACR expression was significantly associated with positive surgical margins (p = 0.01), specifically in tumors with lower Gleason score <7, with ∼95 % exhibiting positive surgical margin (p = 0.008). High AMACR showed marginal association with PSA biochemical recurrence (BCR) (p = 0.06) which was slightly more pronounced in ERG-positive tumors (p = 0.04). This was validated in other public cohorts. However, in this cohort, the association with BCR was not statistically significant in multivariate analysis (p = 0.09). Using in vitro cellular models, AMACR messenger RNA (mRNA) expression, but not protein levels, showed an association with ERG expression. We report for the first time a significant association between AMACR and ERG with prognostic implication. Patients with high AMACR/ERG-positive PCA may be at higher risk for disease progression, and additional studies in larger cohorts are needed to confirm the above findings. Functional studies investigating the molecular pathways connecting AMACR and ERG may provide an additional insight into PCA progression pathways.
α-甲基酰基辅酶A消旋酶(AMACR)是一种特征明确的标志物,在前列腺癌(PCA)诊断中被广泛应用。然而,AMACR表达的预后价值及其与TMPRSS2-ERG基因重排(PCA中最常见的分子改变之一)的关系尚未得到充分研究。在一组218例接受根治性前列腺切除术治疗的局限性PCA男性患者中研究了AMACR表达,并将其与ERG以及各种临床和病理参数相关联。体外研究评估了AMACR对ERG敲低和其他相关基因的变化。此外,生物信息学验证了AMACR/ERG表达的意义,并评估了与AMACR/ERG表达相关的基因特征。AMACR表达与疾病进展以及ERG显著相关(p约为0)。17%的癌灶AMACR表达为阴性/弱阳性,而ERG为阳性。高AMACR表达与手术切缘阳性显著相关(p = 0.01),特别是在Gleason评分<7的肿瘤中,约95%表现为手术切缘阳性(p = 0.008)。高AMACR与前列腺特异性抗原生化复发(BCR)呈边缘性关联(p = 0.06),在ERG阳性肿瘤中略为明显(p = 0.04)。这在其他公共队列中得到了验证。然而,在该队列中,多变量分析显示与BCR的关联无统计学意义(p = 0.09)。使用体外细胞模型,AMACR信使核糖核酸(mRNA)表达而非蛋白水平与ERG表达相关。我们首次报告了AMACR与ERG之间具有预后意义的显著关联。AMACR/ERG阳性的高PCA患者疾病进展风险可能更高,需要在更大队列中进行更多研究以证实上述发现。研究连接AMACR和ERG的分子途径的功能研究可能会为PCA进展途径提供更多见解。